HRP20191491T1 - Biotin za liječenje demijelinizirajućih neuropatija - Google Patents

Biotin za liječenje demijelinizirajućih neuropatija Download PDF

Info

Publication number
HRP20191491T1
HRP20191491T1 HRP20191491T HRP20191491T1 HR P20191491 T1 HRP20191491 T1 HR P20191491T1 HR P20191491 T HRP20191491 T HR P20191491T HR P20191491 T1 HRP20191491 T1 HR P20191491T1
Authority
HR
Croatia
Prior art keywords
biotin
use according
treatment
patient
daily amount
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Frédéric Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191491(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of HRP20191491T1 publication Critical patent/HRP20191491T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
HRP20191491 2015-03-26 2016-03-25 Biotin za liječenje demijelinizirajućih neuropatija HRP20191491T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis
EP16713833.8A EP3273957B1 (en) 2015-03-26 2016-03-25 Biotin for treating demyelinating neuropathies

Publications (1)

Publication Number Publication Date
HRP20191491T1 true HRP20191491T1 (hr) 2019-11-15

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191491 HRP20191491T1 (hr) 2015-03-26 2016-03-25 Biotin za liječenje demijelinizirajućih neuropatija

Country Status (24)

Country Link
US (2) US10357480B2 (enExample)
EP (2) EP3072513A1 (enExample)
JP (1) JP6752874B2 (enExample)
KR (1) KR20170131543A (enExample)
CN (2) CN111973592A (enExample)
AU (1) AU2016238759B2 (enExample)
BR (1) BR112017020408A2 (enExample)
CA (1) CA2980660A1 (enExample)
CY (1) CY1122374T1 (enExample)
DK (1) DK3273957T3 (enExample)
EA (1) EA034394B1 (enExample)
ES (1) ES2748354T3 (enExample)
HR (1) HRP20191491T1 (enExample)
HU (1) HUE046116T2 (enExample)
IL (1) IL254619B (enExample)
LT (1) LT3273957T (enExample)
MA (1) MA41809B1 (enExample)
ME (1) ME03567B (enExample)
PL (1) PL3273957T3 (enExample)
PT (1) PT3273957T (enExample)
RS (1) RS59149B1 (enExample)
SI (1) SI3273957T1 (enExample)
SM (1) SMT201900548T1 (enExample)
WO (1) WO2016151132A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
US12458607B2 (en) * 2018-12-11 2025-11-04 Myospots Australia Pty Ltd Adhesive pad
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用
EP4225327A4 (en) * 2020-10-09 2024-10-16 TX Medic AB TREATMENT OF MUSCLE ATROPHY WITH DEXTRAN SULFATE
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
PL377612A1 (pl) 2002-09-27 2006-02-06 Biogen Idec Ma Inc. Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
US10654916B2 (en) * 2011-04-21 2020-05-19 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
WO2013010015A2 (en) * 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
US9789092B2 (en) 2013-04-29 2017-10-17 Assistance Publique—Hopitaux de Paris Biotin for use in treating X-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
CY1122374T1 (el) 2021-01-27
MA41809B1 (fr) 2019-12-31
HUE046116T2 (hu) 2020-02-28
ES2748354T3 (es) 2020-03-16
SMT201900548T1 (it) 2019-11-13
US20180125825A1 (en) 2018-05-10
SI3273957T1 (sl) 2019-11-29
BR112017020408A2 (pt) 2018-06-05
LT3273957T (lt) 2019-11-11
IL254619B (en) 2020-03-31
EP3273957A1 (en) 2018-01-31
EP3273957B1 (en) 2019-08-14
IL254619A0 (en) 2017-11-30
AU2016238759A1 (en) 2017-10-05
CN107405335A (zh) 2017-11-28
CN111973592A (zh) 2020-11-24
CA2980660A1 (en) 2016-09-29
PL3273957T3 (pl) 2020-01-31
JP2018512451A (ja) 2018-05-17
PT3273957T (pt) 2019-09-18
NZ735528A (en) 2021-09-24
EA034394B1 (ru) 2020-02-04
US10357480B2 (en) 2019-07-23
EP3072513A1 (en) 2016-09-28
KR20170131543A (ko) 2017-11-29
ME03567B (me) 2020-07-20
MA41809A (fr) 2018-01-30
EA201792124A1 (ru) 2018-04-30
WO2016151132A1 (en) 2016-09-29
AU2016238759B2 (en) 2020-08-06
RS59149B1 (sr) 2019-09-30
JP6752874B2 (ja) 2020-09-09
US20190314342A1 (en) 2019-10-17
DK3273957T3 (da) 2019-11-11

Similar Documents

Publication Publication Date Title
HRP20191491T1 (hr) Biotin za liječenje demijelinizirajućih neuropatija
JP2015038135A5 (enExample)
JP2014111603A5 (enExample)
HRP20150260T1 (hr) Uporaba biotina za lijeäśenje multiple skleroze
HRP20241461T1 (hr) Aprocitentan za uporabu u liječenju hipertenzije i povezanih bolesti u kombinaciji s valsartanom
JP2015083580A5 (enExample)
JP2012193216A5 (enExample)
BR112018012870A2 (pt) métodos e composições para o tratamento de transtornos relacionados à crise
JP2018530578A5 (enExample)
JP2019530706A5 (enExample)
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP2018522028A5 (enExample)
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
JP2018512451A5 (enExample)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2016505050A5 (enExample)
JP2021505669A5 (enExample)
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
HRP20190211T1 (hr) Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti
MX391602B (es) Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso
HRP20191798T1 (hr) Postupak liječenja jetrene encefalopatije
MX387263B (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
JP2015516451A5 (enExample)
JP2017515858A5 (enExample)